DATE:
TIME:
LINK: https://bit.ly/3OuMTGu
1x1 meeting opportunities with management:
This is a live, interactive online event. Investors are invited to ask management questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more at www.virtualinvestorconferences.com
Recent Company Highlights
- The Company disclosed plans to enroll end-stage renal disease (ESRD) with endotoxemia as the first indication to be enrolled in human studies of Sigyn TherapyTM, a medical technology designed to treat pathogen-associated inflammatory disorders that are not addressed with market-cleared drug agents.
- The Company introduced ChemoPrepTM and ChemoPureTM, which comprise a system designed to improve chemotherapy delivery and reduce its toxicity. Current limitation of chemotherapy: Poor delivery and toxicity. Less than 3.5% of infused chemotherapy reaches its target tumor site.
- The Company introduced ImmunePrepTM, a novel commercialization platform designed to enhance the delivery of therapeutic antibodies, including cancer checkpoint inhibitors. Current limitation of therapeutic antibodies: Less than 5% of infused antibodies are delivered to their therapeutic target.
About Sigyn Therapeutics™
Sigyn Therapy™ is being advanced to treat pathogen-associated inflammatory disorders that are not addressed with market-cleared drug agents. Candidate treatment indications include endotoxemia, sepsis (leading cause of hospital deaths), community acquired pneumonia (a leading cause of death among infectious diseases), and emerging drug-resistant bacterial and pandemic viral threats.
The Company recently disclosed plans to initiate human studies of Sigyn TherapyTM in end-stage renal disease (ESRD) patients diagnosed with endotoxemia, a condition associated with multi-organ dysfunction and severe sepsis. In
Beyond the advancement of Sigyn Therapy, the Company believes its therapeutic pipeline is among the most expansive and compelling in the extracorporeal blood purification industry.
ChemoPrep™ and ChemoPure™ comprise a system designed to improve the tumor-site saturation of chemotherapy yet reduce treatment toxicity. ImmunePrepTM is a novel commercialization platform designed to enhance the efficacy of therapeutic antibodies (including cancer checkpoint inhibitors), whose 2022 global market of
To learn more about
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Cautionary Note Regarding Forward-Looking Statements
This information in this press release contains forward-looking statements of
CONTACTS:
Director of Operations
858-353-0800 x100
Charlene@SigynTherapeutics.com
Virtual Investor Conferences
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
Source: Virtual Investor Conferences
2023 GlobeNewswire, Inc., source